Edwards Q2 sales $1.53B (+11% YoY); adj EPS $0.66; raises FY23 guidance

Edwards Lifesciences Corp

2023-Q2 EPS reported $1.06 revenue$2,989,800,000

Q2 sales $1.53B (+11%/+12% constant currency); GAAP EPS $0.50 (incl. IP charge), adjusted EPS $0.66.
TAVR sales $992M (+9%/+10% constant currency); TMTT $48M; Surgical $256M; Critical Care $235M.
Raised FY2023 sales guide to $5.9-$6.1B (prior $5.6-$6.0B), constant currency growth 10-13%.
Adjusted EPS guide raised to $2.50-$2.60 (prior $2.48-$2.60); Q3 guide $1.44-$1.52B sales, $0.55-$0.61 adj EPS.
Adjusted gross margin 77.7% (vs 80.5% YoY); $300M IP payment; cash $1.5B, debt $600M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Edwards Lifesciences Corp updated its second quarter of 2023 guidance (raised).

Period: second quarter of 2023
Guidance: raised
Result: reported results

Exact text from the filing

On July 26, 2023, Edwards Lifesciences Corporation, a Delaware corporation (“Edwards”), issued a press release setting forth Edwards’ financial results for the second quarter of 2023.

View on SEC.gov

Browse all earnings releases →

Edwards Lifesciences Corp filing history →

Source: SEC EDGAR

accession 0001099800-23-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.